Business
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
NEW YORK, March 24, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2024 financial results and highlighted recent corporate updates.
About this update from Neurogene Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":331,"url":"https://media.zenfs.com/en/business-wire.com/fa7c3777bc7a09dc23b8fac916291fcd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HITaqNt3QhLuN6ND.rLaVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY2MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/fa7c3777bc7a09dc23b8fac916291fcd","width":480,"height":331}},"lazy":false},{"type":"text","content":"Remains on track to provide regulatory update on registrational trial plans with NGN-401 for Rett syndrome in the first half of 2025","length":132,"tagName":"p","attribs":{}},{"type":"text","content":"Continues to expect to share additional interim clinical data from NGN-401 Phase 1/2 trial in the second half of 2025","length":117,"tagName":"p","attribs":{}},{"type":"text","content":"Received PRIME designation for NGN-401 from the European Medicines Agency","length":73,"tagName":"p","attribs":{}},{"type":"text","content":"Cash runway into the second half of 2027","length":40,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, March 24, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2024 financial results and highlighted recent corporate updates.","length":322,"tagName":"p"},{"type":"text","content":""We believe 2024 was a year of significant progress for our NGN-401 Phase 1/2 trial in Rett syndrome, as we reported encouraging interim efficacy data and NGN-401 was generally well-tolerated at the 1E15 vg dose in a pediatric cohort," said Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. "We remain on track to provide an update on the registrational trial plans in the first half of 2025, and as we look ahead to the second half of 2025, we plan to share additional interim clinical data from the Phase 1/2 trial, including from our 11 years and older cohort."","length":606,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2024 and Recent Highlights, and Anticipated Milestones","length":69,"tagName":"p"},{"type":"text","content":"Phase 1/2 Trial of NGN-401 Gene Therapy for Treatment of Rett Sy...